Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 13/20 | 0.78 |
| ▸ | NR1H3 | Q13133 | 13/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.78 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.78 |
| ▸ | POLB | P06746 | 5/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riccardi C SCHEMBL29606810 | 0.89 | NR1H2 (1.00) | NR1H2NR1H3PTGS1PTGS2POLB | |
| Riccardi C SCHEMBL22704770 | 0.89 | NR1H2 (1.00) | NR1H2NR1H3PTGS1PTGS2POLB | |
| Riccardin D SCHEMBL30335734 | 0.83 | NR1H2 (0.73) | NR1H2NR1H3PTGS1PTGS2POLB | |
| Acerogenin B SCHEMBL13698043 | 0.74 | NFKB1 (0.52) | NR1H2NR1H3PTGS1PTGS2POLB | |
| Acerogenin A SCHEMBL10048511 | 0.74 | NFKB1 (0.52) | NR1H2NR1H3PTGS1PTGS2POLB | |
| Riccardi F SCHEMBL29829924 | 0.74 | NR1H2 (0.74) | NR1H2NR1H3PTGS1PTGS2POLB | |
| SCHEMBL29928907 | 0.72 | NR1H2 (0.68) | NR1H2NR1H3PTGS1PTGS2POLB | |
| SCHEMBL29715970 | 0.68 | PTGS1 (0.53) | NR1H2NR1H3PTGS1PTGS2POLB | |
| SCHEMBL9732911 | 0.62 | NR1H2 (0.42) | NR1H2NR1H3PTGS1PTGS2POLB | |
| Propane SCHEMBL9764268 | 0.61 | TRPA1 (0.38) | NR1H2NR1H3PTGS1PTGS2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260133191-A1 | DETECTION OF AN AMPHIPHILE USING VISUAL INSPECTION OF A LIGAND-MODIFIED SUBSTRATE | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-14 | — | — | US | disclosed |
| US-11345682-B2 | Polymorph of HDAC6-selective inhibitor and application thereof | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345682-B2 | Polymorph of HDAC6-selective inhibitor and application thereof | HDAC6, HDAC1, HDAC3 | NR1H2 65/4885NR1H3 64/4885PTGS1 3266/4885 |
| US-20260133191-A1 | DETECTION OF AN AMPHIPHILE USING VISUAL INSPECTION OF A LIGAND-MODIFIED SUBSTRATE | LIPG, LRBA, CEL | NR1H2 2777/4885NR1H3 2481/4885PTGS1 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.